FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileVertex Pharmaceuticals Incorporated
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
VRTX
Vertex Pharmaceuticals Incorporated Stock AnalysisComprehensive stock analysis for Vertex Pharmaceuticals Incorporated (VRTX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisVRTX
VRTX
Vertex Pharmaceuticals Incorporated
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
VRTX
  1. Home
  2. Stocks
  3. Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

🇺🇸VRTX•NASDAQ

Vertex Pharmaceuticals Incorporated

🇺🇸VRTX•NASDAQ
Market cap
$136.35B
Sentiment

Your view on VRTX

Mkt Cap
$136.35B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Vertex Pharmaceuticals Incorporated

Industry
Biotechnology
Sector
Healthcare
CEO
Reshma Kewalramani FASN,
Headquarters
50 Northern Avenue, Boston, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Reshma Kewalramani FASN,
Headquarters
50 Northern Avenue, Boston, MA, US
Description

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis.

The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.

8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial.

The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.

; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Vertex Pharmaceuticals Incorporated from FRC's valuation model, read against the market price. VRTX last traded at $537.79, 34.3× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Vertex Pharmaceuticals Incorporated. Starting points for Vertex Pharmaceuticals Incorporated: P/E 34.3, EPS $15.68, beta 0.32 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Vertex Pharmaceuticals Incorporated. Vertex Pharmaceuticals Incorporated does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Vertex Pharmaceuticals Incorporated. Trailing twelve-month EPS for Vertex Pharmaceuticals Incorporated stands at $15.68. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$574.33

average of 21 firms, last 12 months

 

$574.33

Low $350.00

Median $576.00

High $665.00

 

Analyst Ratings

Buy23 firms, last 12 months
  • Strong Buy0
  • Buy20
  • Hold2
  • Sell1
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$4.20$4.64$18.16$19.95
Low estimate$3.84$4.13$17.65$18.13
High estimate$5.12$5.05$19.17$21.45
No. of analysts1451717
Year-ago EPS$5.03$4.47$15.32—
Growth-16.6%+3.8%+18.5%—

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$3.50B$3.47B$13.26B$14.73B
Low estimate$3.48B$3.33B$13.19B$14.25B
High estimate$3.52B$3.59B$13.29B$15.30B
No. of analysts1542119
Year-ago revenue$3.19B$2.99B$12.00B—
Growth+9.6%+16.2%+10.5%—
Recent analyst actions15 rating and price-target changes, latest Nov 4, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0, Investing; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Vertex Pharmaceuticals Incorporated. Vertex Pharmaceuticals Incorporated has reported as a listed company since 1991. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold VRTX20 companies · 8 funds
Compare VRTX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ALNYAlnylam Pharmaceuticals, Inc.Biotechnology$21.4B
  • BBIOBridgeBio Pharma, Inc.Biotechnology$15.1B
  • BEAMBeam Therapeutics Inc.Biotechnology$2.2B
  • BMRNBioMarin Pharmaceutical Inc.Biotechnology$11.2B
  • CRSPCRISPR Therapeutics AGBiotechnology$3.9B
  • IONSIonis Pharmaceuticals, Inc.Biotechnology$4.7B
  • NTLAIntellia Therapeutics, Inc.Biotechnology$1.4B
  • PTCTPTC Therapeutics, Inc.Biotechnology$5.1B

More Biotechnology companies

  • PTGXProtagonist Therapeutics, Inc.NASDAQ$8.1B
  • PTHSPelthos Therapeutics Inc.AMEX$28M
  • PTIXProtagenic Therapeutics, Inc.NASDAQ$470,654
  • PTNPalatin Technologies, Inc.NASDAQ$11M
  • PTX.AXPrescient Therapeutics LimitedASX
  • PULMPulmatrix, Inc.NASDAQ$5M
  • PVCTProvectus Biopharmaceuticals, Inc.OTC$19M
  • PVLAPalvella Therapeutics, Inc.NASDAQ$2.1B
  • PXMDPaxMedica, Inc. Common StockOTC$37,879
  • PXXLFPoxel S.A.OTC$13M
  • PYC.AXPYC Therapeutics LimitedASX
  • PYPDPolyPid Ltd.NASDAQ$125M

ETFs holding Vertex Pharmaceuticals Incorporated

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.22%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.19%
  • QQQInvesco QQQ Trust, Series 1$446.1B in assets0.64%
  • IVViShares Core SP 500 ETF$852.9B in assets0.21%
  • BBHVanEck Biotech ETF$536M in assets8.26%
  • LSGRNatixis Loomis Sayles Focused Growth ETF$838M in assets5.25%
  • HHL.TOHarvest Healthcare Leaders Income ETF$2.2B in assets4.94%
  • FBTFirst Trust NYSE Arca Biotechnology Index Fund$3.0B in assets3.48%

Largest holders first, then the funds most concentrated in VRTX.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Vertex Pharmaceuticals Incorporated, and how their positions are changing. At a $136.35B market value, institutional positions materially move Vertex Pharmaceuticals Incorporated's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Vertex Pharmaceuticals Incorporated executives and directors. Shares of Vertex Pharmaceuticals Incorporated have traded between $362.50 and $519.68 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Vertex Pharmaceuticals Incorporated. Vertex Pharmaceuticals Incorporated is a $136.35B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Vertex Pharmaceuticals Incorporated. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Vertex Pharmaceuticals Incorporated. Coverage tracks Vertex Pharmaceuticals Incorporated within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Vertex Pharmaceuticals Incorporated.

VRTX Analysis
Good
Past4
Growth4
Health5
Profit4
Value1

News

Latest Market News